Further technical improvements e.g. by allowing higher numbers of CAR T cells infiltrating the tumor and yielding higher amounts of secreted tTF-NGR payload may open promising avenues for double-targeted cellular therapy of solid tumors. This evidence concerns the gene RTN4R and neoplasm.